Iconovo AB publ
Interim report 1 January — 30 June 2018
Second quarter in brief
Intensive project work was carried out during the second quarter in the three ongoing client projects. The projects progressed according to plan, and partial deliveries billed at the end of the quarter in all the projects.
Iconovo started cooperation on the development of the company’s product platform ICOone with japanese TOA Pharmaceuticals Co., Ltd.
Dr. Mikael Ekström was appointed VP Development at Iconovo AB He takes up his new position in september 2018.
Share in Iconovo AB (publ) was listed on Nasdaq First North, Stockholm, sweden, on 6 april 2018.
The 12 april was registered the company’s rights issue at the Swedish companies registration office, and the company’s share capital increased to 677 600 sek, divided between 6 776 000 shares.
Sales for the second quarter totalled 5 466 thousand (7 771 thousand during the second quarter of 2017).
Operating income for the second quarter amounted to sek 219 (1 226) thousand.
The company added 36 757 thousand (net of issue costs of 3 668 thousand) in cash from the new share issue. As of June 30, 2018, liquid funds amounted to 56 885 (29 263) thousand.
Accounts receivable increased in the quarter by 4 507 thousand, then partial deliveries billed at the end of the quarter. Cash flow from operating activities during the second quarter amounted to -4 082 (-200) thousand, and the net cash flow amounted to 32 337 (19 994) thousand
Shareholders ‘ equity per 30 June 2018 amounted to 64 473 (29 761) thousand.
Significant events after the end of the quarter
The company has in July signed an agreement with the multinational company Stevanato Group relating to manufacturing, international marketing, sales and distribution of its kapselbaserade inhaler ICOcap. As part of the agreement will Iconovo to get a technology access fee, the equivalent of 200 kEUR and will in the future continue to receive royalties on Stevanatos sale.
Lund, August 10, 2018
The BOARD of directors
This report has not been subject to specific review by the company’s auditor.
For more information, please contact:
That hasn’t travelled Lastow, CEO, +46 462 75 67 77, email@example.com
The information in this press release is such information that Iconovo AB is obligated to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government, for publication on August 10, 2018, at 08:00 CET.
IF ICONOVO AB
Iconovo was founded in 2013 by people with long experience in the inhalationsutveckling. The company develops inhalers with the the related drug reconstitution, which is used mainly to treat Asthma and COPD but Iconovo also possesses the expertise to develop products for new types of inhaled medicines such as vaccines.
By working with Iconovo can pharmaceutical companies and generic drug manufacturers get access to a complete pharmaceutical product and hence eliminate the complex and costly early steps in the development phase. Iconovo license its patented products to its customers and provides a faster way to inhalationsmarknaden with lower risk and at a lower cost.
For more information on the activities available on the www.iconovo.se.
The company is based in Lund and Iconovos shares (ticker ICO) is listed on Nasdaq First North, Stockholm since 6 april 2018. Erik Penser Bank AB is the Company’s Certified Adviser.
Iconovo AB interim report 30 June 2018
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Iconovo AB plc via Globenewswire